# OnCo record nct04782687 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct04782687/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct04782687", "NCT04782687" ;
  schema:name "Study of Selinexor Plus DRd for Newly Diagnosed Multiple Myeloma"@en ;
  schema:description "A phase 2 trial of Selinexor, Daratumumab, Lenalidomide in multiple myeloma, run by US Oncology Research, active and no longer recruiting."@en ;
  schema:url <https://onco.cc/trials/nct04782687/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT04782687> ;
  onco:status "active" ;
  onco:tag "ctgov-ingest" ;
  onco:phase "2" ;
  schema:startDate "2021-09-10" ;
  onco:cancers <https://onco.cc/cancers/multiple-myeloma/> ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/>, <https://onco.cc/technologies/monoclonal-antibody/>, <https://onco.cc/technologies/protac-degrader/> ;
  onco:drugs <https://onco.cc/drugs/selinexor/>, <https://onco.cc/drugs/daratumumab/>, <https://onco.cc/drugs/lenalidomide/> ;
  onco:companies <https://onco.cc/companies/mckesson-us-oncology/> .